Literature DB >> 9814551

The free radical antioxidant vitamin E protects cortical synaptosomal membranes from amyloid beta-peptide(25-35) toxicity but not from hydroxynonenal toxicity: relevance to the free radical hypothesis of Alzheimer's disease.

R Subramaniam1, T Koppal, M Green, S Yatin, B Jordan, J Drake, D A Butterfield.   

Abstract

Amyloid beta-peptide (Abeta) is a key factor in the neurotoxicity of Alzheimer's disease (AD). Recent research has shown that Abeta-mediated neurotoxicity involves free radicals and that Abeta peptides can initiate multiple membrane alterations, including protein oxidation and lipid peroxidation, eventually leading to neuronal cell death. Research also has emphasized the role of 4-hydroxynonenal (HNE), a downstream product of lipid peroxidation, in being able to mimic some of the effects of Abeta peptides. In the current investigation, electron paramagnetic resonance (EPR) studies of spin labeled cortical synaptosomal membrane proteins has been employed to study conformational changes in proteins, spectrophotometric methods have been used to measure protein carbonyl content, and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for mitochondrial function has been used to study the effect of vitamin E on samples that were treated with Abeta or HNE. The free radical dependence of beta-amyloid-associated toxicity was confirmed by the ability of the free radical scavenger vitamin E to prevent the toxic effects of Abeta. In contrast, HNE was still toxic in the presence of vitamin E. These results support our Abeta-associated free radical model for neurotoxicity in AD brain and are discussed with reference to potential therapeutic strategies for AD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9814551     DOI: 10.1023/a:1020754807671

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  50 in total

1.  Increased antioxidant enzyme activity in amyloid beta protein-resistant cells.

Authors:  Y Sagara; R Dargusch; F G Klier; D Schubert; C Behl
Journal:  J Neurosci       Date:  1996-01-15       Impact factor: 6.167

2.  Prevention of hyperoxia-induced alterations in synaptosomal membrane-associated proteins by N-tert-butyl-alpha-phenylnitrone and 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (Tempol).

Authors:  B J Howard; S Yatin; K Hensley; K L Allen; J P Kelly; J Carney; D A Butterfield
Journal:  J Neurochem       Date:  1996-11       Impact factor: 5.372

3.  The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins.

Authors:  R Subramaniam; F Roediger; B Jordan; M P Mattson; J N Keller; G Waeg; D A Butterfield
Journal:  J Neurochem       Date:  1997-09       Impact factor: 5.372

4.  Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation.

Authors:  R J Mark; Z Pang; J W Geddes; K Uchida; M P Mattson
Journal:  J Neurosci       Date:  1997-02-01       Impact factor: 6.167

5.  Amyloid beta peptide (25-35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures.

Authors:  M E Harris; Y Wang; N W Pedigo; K Hensley; D A Butterfield; J M Carney
Journal:  J Neurochem       Date:  1996-07       Impact factor: 5.372

6.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  M Sano; C Ernesto; R G Thomas; M R Klauber; K Schafer; M Grundman; P Woodbury; J Growdon; C W Cotman; E Pfeiffer; L S Schneider; L J Thal
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

Review 7.  Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes.

Authors:  H Esterbauer; R J Schaur; H Zollner
Journal:  Free Radic Biol Med       Date:  1991       Impact factor: 7.376

8.  The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by beta-amyloid peptides.

Authors:  M S Shearman; S R Hawtin; V J Tailor
Journal:  J Neurochem       Date:  1995-07       Impact factor: 5.372

9.  beta-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger.

Authors:  A J Bruce; B Malfroy; M Baudry
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

10.  The acute neurotoxic effect of beta-amyloid on mature cultures of rat hippocampal neurons is attenuated by the anti-oxidant U-78517F.

Authors:  U Kumar; D M Dunlop; J S Richardson
Journal:  Int J Neurosci       Date:  1994-12       Impact factor: 2.292

View more
  14 in total

Review 1.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

Review 2.  Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Brain Res Brain Res Rev       Date:  2005-01-08

3.  Exploring the structure of the 100 amino-acid residue long N-terminus of the plant antenna protein CP29.

Authors:  Maryam Hashemi Shabestari; Cor J A M Wolfs; Ruud B Spruijt; Herbert van Amerongen; Martina Huber
Journal:  Biophys J       Date:  2014-03-18       Impact factor: 4.033

Review 4.  Employing new cellular therapeutic targets for Alzheimer's disease: a change for the better?

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2005-01       Impact factor: 1.990

5.  The antioxidant vitamin E modulates amyloid beta-peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease.

Authors:  S M Yatin; M Aksenov; D A Butterfield
Journal:  Neurochem Res       Date:  1999-03       Impact factor: 3.996

Review 6.  Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.

Authors:  Ghiam Yamin; Kenjiro Ono; Mohammed Inayathullah; David B Teplow
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

7.  Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview.

Authors:  D Metodiewa; C Kośka
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

Review 8.  The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment.

Authors:  D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-07-01       Impact factor: 7.376

Review 9.  Dopaminergic agonists: possible neurorescue drugs endowed with independent and synergistic multisites of action.

Authors:  Daniela Uberti; Irene Bianchi; Luca Olivari; Giulia Ferrari-Toninelli; Sara A Bonini; Maurizio Memo
Journal:  Neurochem Res       Date:  2007-05-08       Impact factor: 3.996

10.  Spin trapping and cytoprotective properties of fluorinated amphiphilic carrier conjugates of cyclic versus linear nitrones.

Authors:  Grégory Durand; Robert A Prosak; Yongbin Han; Stéphanie Ortial; Antal Rockenbauer; Bernard Pucci; Frederick A Villamena
Journal:  Chem Res Toxicol       Date:  2009-09       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.